COMP <GO>
ENTX vs ETRA // EV/EBITDA & P/E VALUATION
Entera Bio Ltd. (NASDAQ) VS. Electra Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ENTX 2
— ETRA 0
■ METRIC PARITY
LAST: $3.12 (+0.65%) • MKT CAP: $542.6M
valuation
—
LAST: $8.64 (-3.79%) • MKT CAP: $542.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTX VS. ETRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENTX | ETRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -33.60% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.6 | 28.5 | +35.10 | ENTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $542.6M | $542.3M | $331.5K | ENTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENTX REV | ETRA REV | ENTX GROSS % | ETRA GROSS % | ENTX FCF | ETRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $42.0K | — | 0.0% | — | -$7.5M | — |
| FY 2024 | $181.0K | — | 5.0% | — | -$6.8M | — |
| FY 2023 | $0 | — | — | — | -$7.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTX // BETA —
ETRA // BETA —